CClinicalTrials.gg
Status unknownNCT04302363IMMDCUpdated Mar 10, 2020

Analysis of Intestinal Microflora Combined With DNA Methylation in Stool to Detect Colorectal Cancer

An observational study in Gastrointestinal Microbiome, DNA Methylation and Colorectal Neoplasms, sponsored by WEIDONG LIU,MD. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-03-10.

Sponsored by WEIDONG LIU,MD · Observational

The sponsor has not verified this record recently (last verified Mar 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
500
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Introduction: Colorectal cancer (CRC) has the third highest incidence rate and the fourth mortality rate in the world. Traditional colonoscopy as an invasive examination method cannot be widely used in screening for colorectal neoplasia. The fecal immunochemical test has some limitations in sensitivity. Also, race and regional differences may affect results. Abnormality in the composition of the gut microbiota has been implicated as a potentially important etiologic factor in the initiation and progression of colorectal cancer. Analyzing fecal flora and exfoliated cell genes may represent a new screening tool for colorectal cancer.This research aims to use 16S rRNA to compare differences in fecal flora between colorectal cancer patients and healthy controls. These data combined with DNA findings of fecal exfoliated cells may further clarify this difference to build a model for screening early colorectal cancer in Chinese people.

Methods and analysis: In total, 300 patients with positive colonoscopy results and 200 health controls will be recruited. All participants will complete an information form and questionnaires. Fecal samples will be examined by 16S rRNA analysis. Gene methylation levels will be detected in fecal exfoliated cells. Models of related intestinal microbiota and methylation genes will be built. Receiver operating characteristic (ROC) curve analysis will be used to select some models with appropriate sensitivity and specificity.The models will be further validated by multicenter studys.

Read the detailed description

Introduction: Colorectal cancer (CRC) has the third highest incidence rate and the fourth mortality rate in the world. In China, CRC is the fifth leading cause of cancer deaths. Age-standardized incidence rates in CRC have shown an upward trend.A Westernized lifestyle, particularly physical inactivity, and an increase in the prevalence of obesity in recent decades in China may explain the increase in CRC incidence .

The 5-year survival rate for people with CRC is 65%. Survival rates for CRC can vary depending on various factors, particularly cancer stage. The 5-year survival rate with localized-stage CRC is 90%. About 39% of patients are diagnosed at this early stage. Because of the lack of typical clinical symptoms, early CRC is difficult to detect, and most patients are already in the advanced stage when CRC is diagnosed, thus missing the best intervention stage. Therefore, early detection and early treatment are effective means to reduce the mortality with CRC. Screening has benefits, including diagnosis at an earlier stage, reduced incidence of CRC and reduced mortality.

At present, the main screening methods for CRC are fecal occult blood test and colonoscopy. Colonoscopy is the gold standard for screening for CRC. However, traditional colonoscopy, an invasive examination method, cannot be widely used in screening for colorectal neoplasia.

Fecal samples are easily obtained.Using feces to screen CRC is the current research consensus. According to the most updated Asia Pacific consensus recommendations for CRC screening,FIT(fecal immunochemical test) is used to select high-risk patients for colonoscopy. FIT has also been widely used in other world regions . The sensitivity of FIT is limited (0.79; 95% CI, 0.69-0.86), and a recent systematic meta-analysis showed wide variation in sensitivity among studies . In addition, race and regional differences may affect test results. Therefore, the early screening methods which is non-invasive, highly sensitive and suitable for Chinese people are needed.

Detection of molecular biomarkers in feces for non-invasive diagnosis of CRC may be a promising alternative to detecting blood/plasma biomarkers in current clinical settings. Abnormalities in the composition of the gut microbiota have been implicated as potentially important causes of CRC. With the widespread use of metagenomic sequencing and pyrosequencing in intestinal microbiota research, more bacteria have been found positively associated with CRC incidence. In a recent study, 16S rRNA sequencing was used to classify microbial communities in human intestinal mucosa at different stages of colorectal tumorigenesis, and Fusobacterium was found enriched in colorectal tumors.

For CRC, the main process of benign polyps becoming malignant tumors is the accumulation of genetic and epigenetic alterations that transform colonic epithelial cells into colon adenocarcinoma cells. These cells are continuously shed into colonic lumen and mixed with the stool. During tumor formation, epigenetic changes may occur earlier than mutations. Deregulation of epigenetic mechanisms plays an important role in cancer. Most epigenetic changes in cancer are triggered by genomic alterations in specific genes that are involved in controlling one of the epigenetic mechanisms.Aberrant DNA methylation of tumor suppressor genes induces abnormal expression of downstream genes, which is an important step in the process of tumorigenesis.The methylation status of DNA changes during CRC progression. A number of gene methylation abnormalities associated with CRC discovered in recent studies include SFRP2, SEPT9, BMP3, NDRG4, and SPG20. In addition, some gene mutations are related to CRC. For example, TP53 and KRAS mutations are common in CRC.

In previous research the investigators found that SEPT9, NDRG4, and SDC2 had higher frequency and level of methylation in tumors than in normal or non-tumor adjacent CRC tissues, indicating that these methylated genes may have diagnostic potential for CRC screening. However, BMP3 had very limited contribution to detection accuracy in stool samples. Furthermore, the combination of methylated SEPT9, NDRG4, and SDC2 showed high feasibility of detection of CRC and adenoma and further study showed better performance in detecting CRC than adenoma. Our research also demonstrates differences in fecal genes between different ethnic groups.

This research aims to detect intestinal microbiota differences in stool by 16S rRNA analysis between CRC patients and healthy controls. It will combine DNA analysis of fecal exfoliated cells to further clarify this difference to build some models for screening early colorectal cancer in Chinese people. At the same time, the research will also study the impact of Chinese eating habits on Intestinal Microflora.

02

Conditions studied

  • Gastrointestinal Microbiome
  • DNA Methylation
  • Colorectal Neoplasms

Keywords

  • Gastrointestinal Microbiome
  • DNA Methylation
  • Colorectal Neoplasms
  • Stool
  • biomaker
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's planned enrollment of 500 is above the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

WEIDONG LIU,MD is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

This program was performed in Xiangya Hospital(Still recruiting), Changsha, Hunan, China.

Only participants who received a colonoscopy were enrolled

Inclusion criteria

  • colonoscopy revealing colon or rectal tumor and biopsy-confirmed adenocarcinoma or adenoma.
  • no chemotherapy or surgery, and no history of other cancer.
  • must be able to understand and be willing to sign informed consent.
  • Healthy controls don't have tumors and history of cancer.

Exclusion criteria

Exclusion Criteria:

  • Those who not willing to provide specimens or answer questionnaires before the study began.
  • People whose stool samples does not meet the requirements.
  • People who are unwilling to sign written informed consent or follow a research protocol.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Control Group

    Healthy controls must be 18-75 years old with no tumors and no history of cancer.

    Other: Fecal microbiota detection and exfoliated cell gene detection

  • Test Group

    Inclusion criteria in the experimental group are age 18-75 years old, colonoscopy revealing colon or rectal tumor, biopsy-confirmed adenocarcinoma or adenoma, no chemotherapy or surgery, and no history of other cancer. Both groups must be able to understand and be willing to sign informed consent.

    Other: Fecal microbiota detection and exfoliated cell gene detection

Interventions

  • OtherFecal microbiota detection and exfoliated cell gene detection

    Fecal microbiota detection and exfoliated cell gene detection

06

What researchers measure

Primary outcomes

  1. Diagnostic efficacy of colorectal cancer model in Chinese people

    the difference in intestinal flora and gene methylation between CRC patients and healthy individuals.

    Time frame: 2 years

Secondary outcomes

  1. Effect of diet on intestinal flora and DNA methylation in Chinese people

    Investigate the frequency (e.g. ,"how many times a week"), quantity (e.g. ,"g") and types of food by semi-quantitative food frequency questionnaire (SQFFQ)

    Time frame: 3 years

Other outcomes

  1. Effect of cholecystectomy on intestinal flora and methylation

    All participants complete an information form gathering data on age, sex, occupation, etc. At the same time, we will also collect the history and time of cholecystectomy.

    Time frame: 3 years

  2. Effects of intestinal microflora and DNA methylation under different stool characteristics

    Classification of feces using the Bristol Stool Scale method.Scores from 1 to 7, lower scores indicate harder stool.

    Time frame: 3 years-4years

07

Study locations

1 of 1 sites recruiting
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
    • Liu wei dong, doctor · Contact · davidcsu@foxmail.com · 0086-13873124855
    • mingmei Liao, PhD · Principal investigator
    • xi Xie, PhD · Principal investigator
    • jie Chen · Principal investigator
    • zhan Qu · Principal investigator
    Recruiting
08

References and documents

Publications

  • Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014 Apr 26;383(9927):1490-1502. doi: 10.1016/S0140-6736(13)61649-9. Epub 2013 Nov 11. PubMed 24225001 ↗
  • Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25. PubMed 26808342 ↗
  • Varghese C, Shin HR. Strengthening cancer control in China. Lancet Oncol. 2014 Apr;15(5):484-5. doi: 10.1016/S1470-2045(14)70056-7. No abstract available. PubMed 24731401 ↗
  • Wang YX, Zhu N, Zhang CJ, Wang YK, Wu HT, Li Q, Du K, Liao DF, Qin L. Friend or foe: Multiple roles of adipose tissue in cancer formation and progression. J Cell Physiol. 2019 Dec;234(12):21436-21449. doi: 10.1002/jcp.28776. Epub 2019 May 3. PubMed 31054175 ↗
  • Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017 May 6;67(3):177-193. doi: 10.3322/caac.21395. Epub 2017 Mar 1. PubMed 28248415 ↗
  • Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008 Jun;103(6):1541-9. doi: 10.1111/j.1572-0241.2008.01875.x. Epub 2008 May 13. PubMed 18479499 ↗
  • Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, Matsuda T, Wu KC, Ng S, Leung SY, Makharia G, Chong VH, Ho KY, Brooks D, Lieberman DA, Chan FK; Asia Pacific Working Group on Colorectal Cancer. Asia Pacific consensus recommendations for colorectal cancer screening. Gut. 2008 Aug;57(8):1166-76. doi: 10.1136/gut.2007.146316. PubMed 18628378 ↗
  • Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014 Feb 4;160(3):171. doi: 10.7326/M13-1484. PubMed 24658694 ↗
  • Liang Q, Chiu J, Chen Y, Huang Y, Higashimori A, Fang J, Brim H, Ashktorab H, Ng SC, Ng SSM, Zheng S, Chan FKL, Sung JJY, Yu J. Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer. Clin Cancer Res. 2017 Apr 15;23(8):2061-2070. doi: 10.1158/1078-0432.CCR-16-1599. Epub 2016 Oct 3. PubMed 27697996 ↗
  • Carmona FJ, Azuara D, Berenguer-Llergo A, Fernandez AF, Biondo S, de Oca J, Rodriguez-Moranta F, Salazar R, Villanueva A, Fraga MF, Guardiola J, Capella G, Esteller M, Moreno V. DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. Cancer Prev Res (Phila). 2013 Jul;6(7):656-65. doi: 10.1158/1940-6207.CAPR-12-0501. Epub 2013 May 21. PubMed 23694962 ↗
  • Maleszewska M, Wojtas B, Kaminska B. Deregulation of epigenetic mechanisms in cancer. Postepy Biochem. 2018 Oct 15;64(2):148-156. doi: 10.18388/pb.2018_125. PubMed 30656897 ↗
  • Park SK, Baek HL, Yu J, Kim JY, Yang HJ, Jung YS, Choi KY, Kim H, Kim HO, Jeong KU, Chun HK, Kim K, Park DI. Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population? Intest Res. 2017 Oct;15(4):495-501. doi: 10.5217/ir.2017.15.4.495. Epub 2017 Oct 23. PubMed 29142517 ↗
  • deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grutzmann R, Pilarsky C, Habermann JK, Fleshner PR, Oubre BM, Day R, Sledziewski AZ, Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009 Jul;55(7):1337-46. doi: 10.1373/clinchem.2008.115808. Epub 2009 Apr 30. PubMed 19406918 ↗
  • Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, Daenen KL, Partouns-Hendriks IE, Stessels F, Louwagie J, Smits KM, Weijenberg MP, Sanduleanu S, Khalid-de Bakker CA, Oort FA, Meijer GA, Jonkers DM, Herman JG, de Bruine AP, van Engeland M. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. 2009 Jul 1;101(13):916-27. doi: 10.1093/jnci/djp131. Epub 2009 Jun 17. PubMed 19535783 ↗
  • Okada S, Hata K, Kawai K, Yamamoto Y, Tanaka T, Nishikawa T, Sasaki K, Kaneko M, Emoto S, Murono K, Nozawa H. Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports. Medicine (Baltimore). 2019 Mar;98(12):e14781. doi: 10.1097/MD.0000000000014781. PubMed 30896620 ↗
  • Zeng N, Xiang J. Detection of KRAS G12D point mutation level by anchor-like DNA electrochemical biosensor. Talanta. 2019 Jun 1;198:111-117. doi: 10.1016/j.talanta.2019.01.105. Epub 2019 Jan 31. PubMed 30876538 ↗
  • Chen J, Sun H, Tang W, Zhou L, Xie X, Qu Z, Chen M, Wang S, Yang T, Dai Y, Wang Y, Gao T, Zhou Q, Song Z, Liao M, Liu W. DNA methylation biomarkers in stool for early screening of colorectal cancer. J Cancer. 2019 Aug 28;10(21):5264-5271. doi: 10.7150/jca.34944. eCollection 2019. PubMed 31602277 ↗
  • Rasmussen L, Wilhelmsen M, Christensen IJ, Andersen J, Jorgensen LN, Rasmussen M, Hendel JW, Madsen MR, Vilandt J, Hillig T, Klaerke M, Munster AM, Andersen LM, Andersen B, Hornung N, Erlandsen EJ, Khalid A, Nielsen HJ. Protocol Outlines for Parts 1 and 2 of the Prospective Endoscopy III Study for the Early Detection of Colorectal Cancer: Validation of a Concept Based on Blood Biomarkers. JMIR Res Protoc. 2016 Sep 13;5(3):e182. doi: 10.2196/resprot.6346. PubMed 27624815 ↗
  • Liu S, Wen L, Hou J, Nie S, Zhou J, Cao F, Lu Q, Qin Y, Fu Y, Yu X. Predicting the pathological response to chemoradiotherapy of non-mucinous rectal cancer using pretreatment texture features based on intravoxel incoherent motion diffusion-weighted imaging. Abdom Radiol (NY). 2019 Aug;44(8):2689-2698. doi: 10.1007/s00261-019-02032-0. PubMed 31030244 ↗

Individual participant data

Plan to share: Undecided — Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.The data will be saved in digital form in the excel form and the image will be saved in PNG format.All data will be kept by Professor Wei-dong Liu.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04302363
Lead sponsor
WEIDONG LIU,MD
Collaborators
Natural Science Foundation of Hunan Province
Responsible party
WEIDONG LIU,MD (Director of day surgery center, Xiangya Hospital of Central South University) — Sponsor-investigator
First posted
Mar 10, 2020
Start date
Feb 1, 2018
Primary completion
Dec 1, 2020 (estimated)
Completion
Dec 1, 2021 (estimated)
Last update
Mar 10, 2020

Study contacts

weidong Liu, PhD
Contact
weidong.liu@csu.edu.cn
86-13873124855
mingmei Liao, PhD
Contact
mingmeiliao@csu.edu.cn
86-15388023797
weidong Liu, PhD
study chair · Xiangya Hospital of Central South University
mingmei Liao, PhD
study director · Xiangya Hospital of Central South University
xi Xie, PhD
principal investigator · Xiangya Hospital of Central South University
jie Chen, PhD
principal investigator · Xiangya Hospital of Central South University
zhan Qu, PhD
principal investigator · Xiangya Hospital of Central South University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion